title: Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers.
abstract: We studied the effect of recombinant human erythropoietin (rhEPO) on erythropoiesis when given at different time intervals to healthy adults. 15 volunteers were randomly selected to receive rhEPO (2 x 300 U/kg) and parenteral iron (2 x 200mg) either within a 24 h or 72 h interval. Controls received parenteral iron only. Maximum EPO levels were found 24 h after the first intravenous injection (day 1) with a mean value of 364 and 390 U/l for the rhEPO-treated groups. When second rhEPO administration was after 72 h (group III), volunteers showed significantly higher absolute reticulocyte counts and a higher percentage of young RNA-rich reticulocytes (HFR ratio) over several days compared to those who received rhEPO within a 24 h interval (group II). Both rhEPO-treated groups showed an increase in the mean reticulocyte cell volume. Reticulocyte haemoglobin concentration was inversely correlated with the increasing cell size with a nadir on day 8. Reticulocyte haemoglobin content showed a significant decrease in group II after day 5. Serum ferritin levels showed an inverse pattern to the rate of erythropoiesis. After an initial rise, the serum ferritin decrease was most pronounced in group III. Contrary to previous reports with oral iron supplementation, functional iron deficiency was not seen during rhEPO stimulation, due to parenteral iron administration. Our data suggest that the time has interval between repeated administrations of rhEPO has an important influence on its pharmacodynamics. rhEPO given within an interval of 72 h was more effective in stimulating erythropoiesis than administration within 24 h interval for the same total dose.
authors.affiliation: Department of Obstetrics, University of Zurich, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Breymann
authors.forename: C
authors.initials: C
authors.lastname: Bauer
authors.forename: A
authors.initials: A
authors.lastname: Major
authors.forename: R
authors.initials: R
authors.lastname: Zimmermann
authors.forename: K
authors.initials: K
authors.lastname: Gautschi
authors.forename: A
authors.initials: A
authors.lastname: Huch
authors.forename: R
authors.initials: R
authors.lastname: Huch
mesh_terms: D000328:Adult; D004909:Erythrocyte Indices; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005293:Ferritins / Q000097:blood; D005434:Flow Cytometry; D006801:Humans; D007263:Infusions, Parenteral; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D017701:Reticulocyte Count; D013268:Stimulation, Chemical; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron